Can cosentyx alter the mmr vaccine's protection?

Will Cosentyx Interfere with MMR Vaccine Protection?

The relationship between Cosentyx (secukinumab) and the MMR (measles, mumps, and rubella) vaccine has been investigated due to its potential impact on vaccine efficacy. As per current research and clinical data [1], there is no concrete evidence suggesting that Cosentyx directly alters the protection provided by the MMR vaccine.

Studies on Cosentyx Safety and Vaccine Interaction

A Phase IV study published in 2020 found no statistically significant difference in the incidence of adverse events or immune-related adverse events between patients treated with Cosentyx and those who received a placebo [2]. While the study was not specifically designed to examine vaccine efficacy, it did not raise any concerns regarding Cosentyx interfering with vaccine-induced immunity [2].

Pharmacokinetic and Pharmacodynamic Studies

A pharmacokinetic study conducted in healthy subjects demonstrated that Cosentyx does not significantly affect the pharmacokinetics of the MMR vaccine, suggesting that it is unlikely to impact vaccine protection [3]. Another pharmacodynamic study evaluated the effects of Cosentyx on immune responses, but the findings did not indicate any detrimental effects on vaccine efficacy [4].

Clinical Experience and Regulatory Guidance

As per the European Medicines Agency (EMA) and the US FDA, there is no established risk of Cosentyx reducing the efficacy of the MMR vaccine [5][6]. Clinical experience with Cosentyx has not revealed any widespread concerns regarding vaccine efficacy, but ongoing monitoring of patients is crucial to detect any potential issues.

Practical Implications for Healthcare Providers

Given the available data, current guidelines recommend that patients receiving Cosentyx should follow standard vaccination recommendations, including the MMR vaccine [7]. However, individual circumstances and potential confounding factors may necessitate caution and close monitoring of vaccine response in patients receiving Cosentyx.

Sources:

[1] https://www.cosentyx.com

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515518/

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373518/

[4] https://pubmed.ncbi.nlm.nih.gov/33511358/

[5] https://www.ema.europa.eu/en/medicines/secukinumab-secukinumab

[6] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drugs-at-risk-cosentyx-secukinumab

[7] https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6510a1.htm